1.09% -0.1494

Regenxbio Inc (RGNX)

Regenxbio Inc Aktie (RGNX) Neueste Nachrichten

Regenxbio Inc (RGNX)

Regenxbio Inc Aktie (RGNX) Neueste Nachrichten

REGENXBIO (NASDAQ:RGNX) Rating Lowered to Sell at StockNews.com - Defense World

Quest Partners LLC Has $491,000 Stock Position in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat

REGENXBIO (NASDAQ:RGNX) Shares Down 3.7% - MarketBeat

Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet? - Simply Wall St

REGENXBIO Inc. (NASDAQ:RGNX) Shares Acquired by Principal Financial Group Inc. - Defense World

(RGNX) Trading Report - Stock Traders Daily

Trading Day Review: Regenxbio Inc (RGNX) Gains Momentum, Closing at 11.38 - The Dwinnex

Regenxbio shares keep Buy rating, price target on trial data - Investing.com

Regenxbio shares keep Buy rating, price target on trial data - Investing.com India

Regenxbio shares keep Buy rating, price target on trial data By Investing.com - Investing.com Canada

REGENXBIO’s (RGNX) Buy Rating Reaffirmed at HC Wainwright - Defense World

REGENXBIO Inc. (NASDAQ:RGNX) Director Sells $115,600.00 in Stock - MarketBeat

Assessing Regenxbio: Insights From 5 Financial Analysts - Benzinga

HC Wainwright Reiterates "Buy" Rating for REGENXBIO (NASDAQ:RGNX) - MarketBeat

REGENXBIO (NASDAQ:RGNX) Trading Down 8.5% - MarketBeat

RegenxBio touts positive data for rare disease drug RGX-121 - Clinical Trials Arena

RegenxBio touts positive data for rare disease drug RGX-121 - Yahoo Finance

RegenxBio touts positive data for rare disease drug RGX-121 - Pharmaceutical Technology

REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect - StockTitan

REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

REGENXBIO to Participate in Upcoming Investor Conferences - Winchester Herald Chronicle

Louisiana State Employees Retirement System Raises Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

Panagora Asset Management Inc. Lowers Stake in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat

Gene Therapy Market Size to Reach USD 54.39 Billion By 2032 with CAGR of 23.12%, Boosted by Rising Genetic Disorders and Advances in CRISPR Technology - GlobeNewswire Inc.

REGENXBIO to Participate in Upcoming Investor Conferences - StockTitan

REGENXBIO to Participate in Upcoming Investor Conferences - Yahoo Finance

REGENXBIO (NASDAQ:RGNX) Stock Crosses Below 50-Day Moving Average of $12.32 - MarketBeat

REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium - StockTitan

Opinion: Ruling in REGENXBIO-Sarepta Patent Case Threatens Gene Therapy Market - BioSpace

REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights - Longview News-Journal

Assenagon Asset Management S.A. Buys 588,773 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat

Analyzing REGENXBIO (NASDAQ:RGNX) and Moderna (NASDAQ:MRNA) - Defense World

Comerica Bank Has $312,000 Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - Longview News-Journal

REGENXBIO Inc. (NASDAQ:RGNX) Shares Acquired by Price T Rowe Associates Inc. MD - Defense World

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit - Longview News-Journal

REGENXBIO releases new data on DMD drug ahead of earnings - MSN

Harbor Capital Advisors Inc. Lowers Stock Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

Harbor Capital Advisors Inc. Sells 30,303 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - American Banking and Market News

REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

REGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - Citizentribune

REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - Longview News-Journal

Phase 1/2 update ‘encouraging’ for DMD gene therapy RGX-202 - Muscular Dystrophy News

FY2024 Earnings Forecast for REGENXBIO Inc. Issued By HC Wainwright (NASDAQ:RGNX) - MarketBeat

It is Poised to be a Bull Market for Regenxbio Inc (RGNX) - SETE News

REGENXBIO Inc. to Post FY2024 Earnings of ($4.99) Per Share, HC Wainwright Forecasts (NASDAQ:RGNX) - Defense World

REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Public Employees Retirement System of Ohio - Defense World

REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Public Employees Retirement System of Ohio - MarketBeat

REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Lazard Asset Management LLC - Defense World

Regenxbio Inc (RGNX) rating initates by Goldman - Knox Daily

Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder (RGNX) - Seeking Alpha

REGENXBIO (NASDAQ:RGNX) Price Target Cut to $50.00 by Analysts at Barclays - Defense World

Wall Street Analysts Think Regenxbio (RGNX) Could Surge 234.37%: Read This Before Placing a Bet - Yahoo Finance

Financial Metrics Unveiled: Regenxbio Inc (RGNX)’s Key Ratios in the Spotlight - The Dwinnex

RegenXBio Grants RSUs to Executives Amidst Leadership Transition - TipRanks

REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by Vanguard Group Inc. - Defense World

REGENXBIO (NASDAQ:RGNX) PT Raised to $39.00 - MarketBeat

REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by Vanguard Group Inc. - MarketBeat

REGENXBIO (NASDAQ:RGNX) Price Target Increased to $39.00 by Analysts at HC Wainwright - Defense World

Where Regenxbio Stands With Analysts - Benzinga

Ähnlich wie RGNX